Chronic Lung Allograft Dysfunction.
BOS
CLAD
PPFE
RAS
Journal
Thoracic surgery clinics
ISSN: 1558-5069
Titre abrégé: Thorac Surg Clin
Pays: United States
ID NLM: 101198195
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
10
5
2022
Statut:
ppublish
Résumé
Chronic lung allograft dysfunction (CLAD) is a syndrome of progressive lung function decline, subcategorized into obstructive, restrictive, and mixed phenotypes. The trajectory of CLAD is variable depending on the phenotype, with restrictive and mixed phenotypes having more rapid progression and lower survival. The mechanisms driving CLAD development remain unclear, though allograft injury during primary graft dysfunction, acute cellular rejection, antibody-mediated rejection, and infections trigger immune responses with long-lasting effects that can lead to CLAD months or years later. Currently, retransplantation is the only effective treatment.
Identifiants
pubmed: 35512941
pii: S1547-4127(21)00118-3
doi: 10.1016/j.thorsurg.2021.11.004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-242Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure A. Venado: Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction (PIRCLAD) study sponsored by Genentech (Principal Investigator). J. Kukreja: Lung Bioengineering (Data Safety Monitoring committee); Transmedics (research). John Greenland: Scientific Advisory Board for Atara Biotherapeutics, Theravance Biopharma, Boehringer Ingelheim; Research funding: Theravance Biopharma.